Updated Jul 16, 2026
Stalfort John A III has filed 2 SEC Form 4 filings across 2 companies in the last 90 days — buying.
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-05 | ABOS | Acumen Pharmaceuticals, Inc. | A — Grant or award | 35.5K | $0.00 | |
| 2026-06-02 | TSHA | Taysha Gene Therapies, Inc. | A — Grant or award | 21.3K | $0.00 | |
| 2024-11-26 | VRCA | Verrica Pharmaceuticals Inc. | G — Bona-fide gift | 50.0K | $0.00 | |
| 2024-11-26 | VRCA | Verrica Pharmaceuticals Inc. | P — Open-market purchase | 1.12M | — |
Stalfort John A III is a corporate insider — currently tracked as Director of Acumen Pharmaceuticals, Inc. (ABOS). InsiderAlpha tracks every SEC Form 4 filing in real time.
2 primary Form 4 filings in the last 90 days, covering 2 companies.
Recorded transactions: 3 open-market purchases () and 0 open-market sales () across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Stalfort John A III profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.